Evidence map›Paper›PMID 40964505›Full record

ReviewImmunoTargets and therapy2025

Research Progress of Natural Killer Cells in Hashimoto's Thyroiditis.

Yanchun Wang, Zhangren Yan, Jianhang Miao, Huafa Que, Wei Shan

Abstract readReview
In one paragraph

Review in ImmunoTargets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yanchun Wang *College of Clinical Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, People's Republic of China.ORCID 0000-0003-2903-6202
Zhangren Yan *Department of Traditional Chinese Medicine Surgery, The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, People's Republic of China.
Jianhang MiaoDepartment of General Surgery,Zhongshan City People's Hospital, Zhongshan, Guangdong, People's Republic of China.
Huafa QueTraditional Chinese Medicine Surgery, Longhua Hospital Affiliated to Shanghai University of Chinese Medicine, Shanghai, People's Republic of China.
Wei ShanTraditional Chinese Medicine Surgery, Longhua Hospital Affiliated to Shanghai University of Chinese Medicine, Shanghai, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hashimoto's thyroiditis is one of the most common autoimmune diseases, characterized by lymphocytic infiltration, thyroid autoantibody production, and progressive thyroid destruction. Natural killer cells, as innate immune effectors, play a dual role in HT pathogenesis through cytotoxicity, death receptor signaling, inflammasome activation, and secretion of proinflammatory cytokines. Recent studies using single-cell RNA sequencing have revealed functional heterogeneity of NK subsets, suggesting stage-specific roles in either amplifying or regulating inflammation. Moreover, peripheral blood from HT patients shows increased expression of activating receptors such as NKG2D and NKp30, positively correlated with thyroid autoantibody titers, while abnormal activation of the NLRP3 inflammasome drives NK cell-mediated IFN-γ release and thyroid follicular cell pyroptosis. These advances highlight NK cells as both contributors to immune imbalance and potential therapeutic targets. A better understanding of NK cell-related mechanisms will provide novel insights into disease monitoring and the development of targeted interventions for HT.

Indexed as

cytotoxicityhashimoto’s thyroiditisnatural killer cellsreceptor

Identifiers

PMID40964505
PMCPMC12439844

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.